5 Results for "

Naphthalene scaffold

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "Naphthalene scaffold" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-B0055
CAS No.: 275-51-4
Synonyms: Cyclopentacycloheptene
Azulene (Cyclopentacycloheptene) is as an isomer of naphthalene with high anti-HIV activity. Azulene, isolated from the distillation of chamomile oil, is a scaffold in medicinal chemistry .
loading...
    loading...
Cat. No.: HY-178365
PAD-IN-4 is a potent PAD inhibitor (PAD 1/4, IC50 = 0.273/0.24 μM). PAD-IN-4 shows no significant cytotoxicity against A549 or MDA-MB-231 cells. PAD-IN-4 can be used for the study of cancer and autoimmune diseases .
loading...
    loading...
Cat. No.: HY-B0055R
CAS No.: 275-51-4
Synonyms: Cyclopentacycloheptene (Standard)
Azulene (Standard) is the analytical standard of Azulene. This product is intended for research and analytical applications. Azulene (Cyclopentacycloheptene) is as an isomer of naphthalene with high anti-HIV activity. Azulene, isolated from the distillation of chamomile oil, is a scaffold in medicinal chemistry .
loading...
    loading...
Cat. No.: HY-179593
Target:  

Bacterial

Research Areas:  

Inflammation/Immunology

GM47-1, a naphthalene scaffold derivative, is a potent mycolic acid transporter MmpL3 inhibitor exhibiting potent bactericidal activity against Mycobacterium abscessus (Mabs) with an MIC50 of 2.1 µM. GM47-1 targets MmpL3, disrupts cell wall integrity, and induces ATP leakage and uncouples respiration. GM47-1 can be used for Mycobacterium abscessus pulmonary disease (Mabs-PD) research .
loading...
    loading...
Cat. No.: HY-182354
CAS No.: 861877-12-5
Research Areas:  

Cancer

VEGFR2-IN-84 is an orally active, multi-targeted tyrosine kinase inhibitor based on a naphthalene ring scaffold. VEGFR2-IN-84 inhibits VEGFR2 with sub-nanomolar affinity and broadly targets kinases including Kit, FGFR, PDGFR, and Ret. By competitively binding to the ATP-binding pocket, VEGFR2-IN-84 blocks the phosphorylation of VEGFR2 and its downstream AKT/ERK signaling pathway, thereby significantly inhibiting endothelial cell proliferation, migration, and tumor angiogenesis. VEGFR2-IN-84 exhibits broad-spectrum antiproliferative activity against various solid tumors such as liver cancer, lung cancer, and renal cancer, shows weak toxicity to normal cells, and has superior potency to Lenvatinib (HY-10981). VEGFR2-IN-84 possesses favorable pharmacokinetic properties and high safety (LD50>2000 mg/kg), and can be used in related studies of various malignant tumors .
loading...
    loading...